EE03950B1 - Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine - Google Patents

Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine

Info

Publication number
EE03950B1
EE03950B1 EEP199900293A EEP9900293A EE03950B1 EE 03950 B1 EE03950 B1 EE 03950B1 EE P199900293 A EEP199900293 A EE P199900293A EE P9900293 A EEP9900293 A EE P9900293A EE 03950 B1 EE03950 B1 EE 03950B1
Authority
EE
Estonia
Prior art keywords
bulk density
inhalable
preparation
dosage form
terbutaline sulphate
Prior art date
Application number
EEP199900293A
Other languages
English (en)
Estonian (et)
Inventor
Trofast Jan
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9900293A publication Critical patent/EE9900293A/xx
Publication of EE03950B1 publication Critical patent/EE03950B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP199900293A 1997-01-20 1998-01-13 Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine EE03950B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700136A SE9700136D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000041 WO1998031353A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof

Publications (2)

Publication Number Publication Date
EE9900293A EE9900293A (et) 2000-02-15
EE03950B1 true EE03950B1 (et) 2003-02-17

Family

ID=20405456

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900293A EE03950B1 (et) 1997-01-20 1998-01-13 Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine

Country Status (30)

Country Link
EP (1) EP1014955B1 (is)
JP (1) JP2001509812A (is)
KR (1) KR100528415B1 (is)
CN (1) CN1195507C (is)
AT (1) ATE263552T1 (is)
AU (1) AU728768B2 (is)
BE (1) BE1012009A5 (is)
BR (1) BR9806893A (is)
CA (1) CA2277891C (is)
CZ (1) CZ295665B6 (is)
DE (1) DE69823045T2 (is)
EE (1) EE03950B1 (is)
ES (2) ES2217535T3 (is)
FR (1) FR2759905B1 (is)
GR (1) GR980100023A (is)
HU (1) HUP0000755A3 (is)
ID (1) ID21929A (is)
IE (1) IE980026A1 (is)
IL (1) IL130839A (is)
IS (1) IS2072B (is)
NL (1) NL1008020C2 (is)
NO (1) NO993540L (is)
NZ (1) NZ336595A (is)
PL (1) PL189551B1 (is)
RU (1) RU2180562C2 (is)
SE (1) SE9700136D0 (is)
SK (1) SK283943B6 (is)
TR (1) TR199901689T2 (is)
UA (1) UA57765C2 (is)
WO (1) WO1998031353A1 (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
EP2255807A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
HU222355B1 (hu) * 1993-10-01 2003-06-28 Astra Aktiebolag Eljárás és berendezés finom gyógyszerhatóanyag-porok kezelésére és feldolgozására
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
IL130839A0 (en) 2001-01-28
ES2149083B1 (es) 2001-05-16
CN1244120A (zh) 2000-02-09
HUP0000755A3 (en) 2001-03-28
IL130839A (en) 2004-12-15
RU2180562C2 (ru) 2002-03-20
AU5786098A (en) 1998-08-07
KR20000070189A (ko) 2000-11-25
SK283943B6 (sk) 2004-05-04
GR980100023A (el) 1998-09-30
NL1008020A1 (nl) 1998-07-22
HUP0000755A2 (hu) 2000-10-28
UA57765C2 (uk) 2003-07-15
WO1998031353A1 (en) 1998-07-23
CN1195507C (zh) 2005-04-06
PL334526A1 (en) 2000-02-28
ID21929A (id) 1999-08-12
IS2072B (is) 2005-12-15
CA2277891A1 (en) 1998-07-23
FR2759905A1 (fr) 1998-08-28
SK96099A3 (en) 2000-01-18
CA2277891C (en) 2006-08-29
NZ336595A (en) 2001-01-26
CZ295665B6 (cs) 2005-09-14
ATE263552T1 (de) 2004-04-15
KR100528415B1 (ko) 2005-11-15
BE1012009A5 (fr) 2000-04-04
ES2217535T3 (es) 2004-11-01
NL1008020C2 (nl) 2000-01-18
ES2149083A1 (es) 2000-10-16
AU728768B2 (en) 2001-01-18
EP1014955A1 (en) 2000-07-05
NO993540L (no) 1999-09-20
EE9900293A (et) 2000-02-15
EP1014955B1 (en) 2004-04-07
NO993540D0 (no) 1999-07-19
SE9700136D0 (sv) 1997-01-20
IS5107A (is) 1999-07-06
FR2759905B1 (fr) 2001-03-09
PL189551B1 (pl) 2005-08-31
JP2001509812A (ja) 2001-07-24
DE69823045T2 (de) 2004-10-21
IE980026A1 (en) 1998-10-07
DE69823045D1 (de) 2004-05-13
TR199901689T2 (xx) 1999-09-21
CZ255899A3 (cs) 1999-10-13
BR9806893A (pt) 2000-05-16

Similar Documents

Publication Publication Date Title
SE9700135D0 (sv) New formulation
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
EE03998B1 (et) Inhaleeritav budesoniidi sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml
EE03950B1 (et) Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090113